PharmaCyte Biotech Inc (PMCB): PharmaCyte up 10% on positive biocompati...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	23
Posts	2036
Boards Moderated	0
Alias Born	12/06/2017

longboarder7892

Re: None

Thursday, 09/16/2021 10:08:13 AM

Thursday, September 16, 2021 10:08:13 AM

PharmaCyte up 10% on positive biocompatibility study results for CypCaps
Sep. 16, 2021 9:56 AM ETPharmaCyte Biotech, Inc. (PMCB)By: Jonathan M Block, SA News Editor
Laboratory
nicolas_/E+ via Getty Images
Shares of PharmaCyte Biotech (NASDAQ:PMCB) are up 10% in morning trading as the company announced positive test results on biocompatibility studies of its CypCaps cellulose sulphate capsules.
Results showed that the capsule material does not activate the body’s the complement system, which is involved in immune and inflammatory responses.
PharmaCyte uses its proprietary live-cell encapsulation technology, Cell-in-a-Box, which involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form.
Last month, the company said it would expand its product pipeline to include diabetes and malignant ascites programs.
Read: PharmaCyte expands product pipeline to include diabetes and malignant ascites